If you reread yesterday's PR it does bring a diffe
Post# of 72444
(Total Views: 357)
Posted On: 03/16/2018 5:03:46 PM
If you reread yesterday's PR it does bring a different light to B-OM.
One, if you are a BP and possible partner, the understanding that IPIX is working on moving to sachets is a big deal in the real world and will cost millions less going that route in Manufacturing, Shipping and Logistics. Imagine a company that has to bottle and ship listerine size bottles or packages - and for a 7 week course? That is alot of bottles and alot of manufacturing and cost!!!! Really think about that! Giving little splenda style packets that you mix with water is a billion dollar transition alone.....
Next - the fact that they mention they see B-OM as being a NO DOUBT drug to be prescribed for every patient that will have Chemo Radiation for HNC is unreal.... 65,000 (worldwide, ~750,000 cases annually)
Then the plan will be to broaden the label of B-OM to cover all Chemo Radiation patients including HSTC - the numbers become unthinkable --- in the US Alone ---- 650,000 people annually in the U.S alone! World Wide?????? Hundreds of Millions. All will have the ability to be prescribed B-OM for prevention.
If they do get there -- IF ---- this stock would be in untouchable. 2 Billion untapped market for HNC - add the other cancers that require CR - you are talking what??? BILLION(S) upon BILLION(S)
That is why you invest in a company. Great science in unmet area's...
One, if you are a BP and possible partner, the understanding that IPIX is working on moving to sachets is a big deal in the real world and will cost millions less going that route in Manufacturing, Shipping and Logistics. Imagine a company that has to bottle and ship listerine size bottles or packages - and for a 7 week course? That is alot of bottles and alot of manufacturing and cost!!!! Really think about that! Giving little splenda style packets that you mix with water is a billion dollar transition alone.....
Next - the fact that they mention they see B-OM as being a NO DOUBT drug to be prescribed for every patient that will have Chemo Radiation for HNC is unreal.... 65,000 (worldwide, ~750,000 cases annually)
Then the plan will be to broaden the label of B-OM to cover all Chemo Radiation patients including HSTC - the numbers become unthinkable --- in the US Alone ---- 650,000 people annually in the U.S alone! World Wide?????? Hundreds of Millions. All will have the ability to be prescribed B-OM for prevention.
If they do get there -- IF ---- this stock would be in untouchable. 2 Billion untapped market for HNC - add the other cancers that require CR - you are talking what??? BILLION(S) upon BILLION(S)
That is why you invest in a company. Great science in unmet area's...
(10)
(0)